Literature DB >> 12781109

[Ambulatory blood pressure monitoring in multicystic dysplastic kidney disease].

R Pardo de la Vega1, D Herrero Morín, F A Ordóñez Alvarez, V Martínez Suárez, F Santos Rodríguez, S Málaga Guerrero.   

Abstract

OBJECTIVE: To evaluate blood pressure in a group of patients with multicystic dysplastic kidney (MDK) disease through ambulatory blood pressure (ABP) monitoring. PATIENTS AND METHODS: ABP monitoring was performed in 16 patients with MDK disease using a Spacelabs 90207 monitor and an appropriately sized armband. The patients performed their normal daily activities except physical exercise. The activity period was 8:00 am to 8:00 pm and the resting period was midnight to 6:00 am. Patients with a percentage of correct readings of less than 70 % were excluded. The mean systolic and diastolic blood pressures for each period were calculated. Circadian variability was determined by the ratio between mean systolic and diastolic values in the active and resting periods, respectively. The results were compared with ABP values in healthy children.
RESULTS: Fourteen patients (mean age 16 3.1 years, range: 6-27.6) were included. No patients with hypertension were found through casual measurement. One patient had daytime systolic hypertension. Five patients presented an abnormal drop in blood pressure during sleep.
CONCLUSION: Blood pressure should be monitored in patients with MDK disease. ABP monitoring may detect alterations that can go unnoticed in casual determinations. Further studies with large samples are needed to establish the real prevalence of hypertension in these patients.

Entities:  

Mesh:

Year:  2003        PMID: 12781109     DOI: 10.1016/s1695-4033(03)78119-3

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  1 in total

Review 1.  Management and etiology of the unilateral multicystic dysplastic kidney: a review.

Authors:  David S Hains; Carlton M Bates; Susan Ingraham; Andrew L Schwaderer
Journal:  Pediatr Nephrol       Date:  2008-05-15       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.